What is Delstrigo
When to interrupt dosageThe suggested dosage of Delstrigo is based on the identified affliction, including Anti-Retroviral Agents, High Risk Patients and Chronic Hepatitis B. The measure of dosage fluctuates, depending on the procedure of delivery (e.g. Tablet or Tablet, film coated) provided in the table below.
WarningsThere are 20 known major drug interactions with Delstrigo.
Delstrigo Novel Uses: Which Conditions Have a Clinical Trial Featuring Delstrigo?Currently, 46 active clinical trials are assessing the potential of Delstrigo to replace a current antiretroviral treatment regimen for certain virologically suppressed (HIV1 RNA <50 copies/mL) adult patients on a stable regimen at the start of therapy, as well as in treating Chronic Hepatitis B and HIV (Human Immunodeficiency Virus).
Delstrigo Reviews: What are patients saying about Delstrigo?
Patient Q&A Section about delstrigo
What are the side effects of Delstrigo?
"The most common side effects of Delstrigo include abnormal dreams, difficulty sleeping, nightmares, depression, headaches, dizziness, drowsiness, coughing, an irritated or runny nose, nausea, diarrhea, abdominal pain, vomiting, hair loss, rashes, muscle disorders, fatigue, and fever." - Anonymous Online Contributor
What does Delstrigo do?
"The DELSTRIGO prescription medication is used to treat HIV-1 infection in adults who have not received HIV-1 medicines in the past, or to replace their current HIV-1 medicines. This decision is made by the patient's healthcare provider after determining that the patient meets certain requirements." - Anonymous Online Contributor
Who manufactures Delstrigo?
"The European Commission red lighted Merck's DELSTRIGO (doravirine / lamivudine / tenofovir disoproxil fumarate), a once-daily fixed-dose combination tablet as a complete regimen and PIFELTRO (doravirine), an NNRTI, both for the treatment of HIV-1 in [the European Union]." - Anonymous Online Contributor
How good is Delstrigo?
"In a study of 728 adults, 84% of those treated with Delstrigo had undetectable HIV levels in their blood (fewer than 40 copies/ml) after 48 weeks, compared to 80% of those given a combination of efavirenz, emtricitabine, and tenofovir disoproxil." - Anonymous Online Contributor